[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 64, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 943020, "exercisedValue": 0, "unexercisedValue": 137562}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 77, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 48125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 648600, "exercisedValue": 0, "unexercisedValue": 54705}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 58, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 721087, "exercisedValue": 0, "unexercisedValue": 86025}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preetam  Shah M.B.A., Ph.D.", "age": 51, "title": "Chief Strategy & Financial Officer and Treasurer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1751328000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.81, "open": 9.7649, "dayLow": 9.51, "dayHigh": 10.0891, "regularMarketPreviousClose": 9.81, "regularMarketOpen": 9.7649, "regularMarketDayLow": 9.51, "regularMarketDayHigh": 10.0891, "payoutRatio": 0.0, "beta": 2.109, "forwardPE": -3.8482492, "volume": 35141, "regularMarketVolume": 35141, "averageVolume": 42196, "averageVolume10days": 42230, "averageDailyVolume10Day": 42230, "bid": 9.82, "ask": 0.0, "bidSize": 1, "askSize": 0, "marketCap": 158210336, "fiftyTwoWeekLow": 3.7, "fiftyTwoWeekHigh": 10.39, "fiftyDayAverage": 7.7868, "twoHundredDayAverage": 6.52488, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 145507136, "profitMargins": 0.0, "floatShares": 10299137, "sharesOutstanding": 15997000, "sharesShort": 411360, "sharesShortPriorMonth": 274548, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0257, "heldPercentInsiders": 0.43874002, "heldPercentInstitutions": 0.10263, "shortRatio": 8.82, "shortPercentOfFloat": 0.0398, "impliedSharesOutstanding": 15997000, "bookValue": 0.558, "priceToBook": 17.724014, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -51280000, "trailingEps": -3.97, "forwardEps": -2.57, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -3.22, "52WeekChange": 1.0060852, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 9.89, "targetHighPrice": 13.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.5, "targetMedianPrice": 12.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 18351000, "totalCashPerShare": 1.148, "ebitda": -45189000, "totalDebt": 5791000, "quickRatio": 1.608, "currentRatio": 1.834, "debtToEquity": 65.038, "returnOnAssets": -1.08033, "returnOnEquity": -7.44591, "freeCashflow": -20963500, "operatingCashflow": -35065000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Elicio Therapeutics, Inc.", "marketState": "CLOSED", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1753480126, "regularMarketTime": 1753473601, "exchange": "NCM", "messageBoardId": "finmb_214936128", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.815494, "regularMarketPrice": 9.89, "longName": "Elicio Therapeutics, Inc.", "postMarketChangePercent": 1.11223, "postMarketPrice": 10.0, "postMarketChange": 0.11, "regularMarketChange": 0.0799999, "regularMarketDayRange": "9.51 - 10.0891", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 42196, "fiftyTwoWeekLowChange": 6.1900005, "fiftyTwoWeekLowChangePercent": 1.672973, "fiftyTwoWeekRange": "3.7 - 10.39", "fiftyTwoWeekHighChange": -0.5, "fiftyTwoWeekHighChangePercent": -0.048123192, "fiftyTwoWeekChangePercent": 100.60851, "earningsTimestamp": 1747166702, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.97, "epsForward": -2.57, "epsCurrentYear": -2.405, "priceEpsCurrentYear": -4.1122665, "fiftyDayAverageChange": 2.1032004, "fiftyDayAverageChangePercent": 0.27009818, "twoHundredDayAverageChange": 3.3651204, "twoHundredDayAverageChangePercent": 0.51573676, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Angion Biomedica Corp.", "nameChangeDate": "2025-07-24", "averageAnalystRating": "1.5 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "displayName": "Elicio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]